These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34905144)

  • 1. Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials.
    Gonzalez PL; Rappo U; Akinapelli K; McGregor JS; Puttagunta S; Dunne MW
    Infect Dis Ther; 2022 Feb; 11(1):423-434. PubMed ID: 34905144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
    Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
    N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials.
    Gonzalez PL; Rappo U; Mas Casullo V; Akinapelli K; McGregor JS; Nelson J; Nowak M; Puttagunta S; Dunne MW
    Infect Dis Ther; 2021 Mar; 10(1):471-481. PubMed ID: 33515414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection in Patients With Obesity or Diabetes: A Subgroup Analysis of Pooled Phase 3 Clinical Trials.
    Riccobene T; Lock J; Lyles RD; Georgiades B; Nowak M; Gonzalez PL; Park J; Rappo U
    Open Forum Infect Dis; 2023 Jun; 10(6):ofad256. PubMed ID: 37305839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
    Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
    Trials; 2022 May; 23(1):407. PubMed ID: 35578360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
    Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
    Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin.
    Juul JJ; Mullins CF; Peppard WJ; Huang AM
    Ther Clin Risk Manag; 2016; 12():225-32. PubMed ID: 26937194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA.
    Riccobono E; Giani T; Baldi G; Arcangeli S; Antonelli A; Tellone V; Del Vecchio A; De Joannon AC; Rossolini GM
    Int J Antimicrob Agents; 2022 Feb; 59(2):106503. PubMed ID: 34929289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
    Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
    Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study.
    Ioannou P; Wolff N; Mathioudaki A; Spanias C; Spernovasilis N; Kofteridis DP
    Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.
    Smith JR; Roberts KD; Rybak MJ
    Infect Dis Ther; 2015 Sep; 4(3):245-58. PubMed ID: 26341488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.
    Raad I; Darouiche R; Vazquez J; Lentnek A; Hachem R; Hanna H; Goldstein B; Henkel T; Seltzer E
    Clin Infect Dis; 2005 Feb; 40(3):374-80. PubMed ID: 15668859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
    Pfaller MA; Mendes RE; Duncan LR; Flamm RK; Sader HS
    J Antimicrob Chemother; 2018 Oct; 73(10):2748-2756. PubMed ID: 29982565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
    Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
    Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dalbavancin: a new lipoglycopeptide antibiotic.
    Bailey J; Summers KM
    Am J Health Syst Pharm; 2008 Apr; 65(7):599-610. PubMed ID: 18359966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
    Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
    Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
    Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
    Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections.
    Giorgobiani M; Burroughs MH; Antadze T; Carrothers TJ; Riccobene TA; Patel R; Lin T; Stefanova P
    Pediatr Infect Dis J; 2023 Mar; 42(3):199-205. PubMed ID: 36476623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.